skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration

In this report, we cover catalysts from 36 drugs, devices and diagnostics expected to occur in early 2017. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.

 

Highlights of indications covered:

  • Acute Pain
  • Atopic Dermatitis (Eczema)
  • Attention Deficit Hyperactivity Disorder (ADHD)
  • Cardiac Valve Surgery
  • Chronic Pain
  • Coronary Artery Disease
  • Cystic Fibrosis (CF) 

 

 

Read also

  • Scrip

    Pharma's Orphan Drug Activity Infographic

    27 Feb 2017

    More than two-fifths of new drugs approved in the US last year were orphan drugs, and there are more than 4,500 drugs in active development for rare diseases. Effective orphan drug legislation and incentivization programs introduced gradually around the world since the 1980s mean rare diseases are no longer a rare sighting in the pharma industry pipeline, as this infographic illustrates.

    Topics Rare Disease

  • Medtech Insight

    More EU Notified Bodies Bite The Dust

    By Amanda Maxwell 22 May 2017

    The number of notified bodies operating under the EU's current medical device directives continue to decline, and that trend is expected to persist with the new regulations entering into force.

  • Scrip

    eTheRNA CEO outlines development plan in cancer RNA space

    Mike Ward, global director of content for Informa Pharma Intelligence, interviews Dirk Reyn, CEO of eTheRNA, on the sidelines of the BIO-Europe partnering conference in Cologne, Germany. The pair discusses eTheRNA's emerging cancer immunotherapy pipeline, funding prospects and the next steps for the company—which was founded in 2013—as it looks to expand its business.

;

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888-670-8900
  • US Toll           : +1 908-547-2200
  • UK & Europe : +44 (20) 337 73737
  • Australia       : +61 2 8705 6907

Or email us your inquiry, so we can provide you the best possible customer service:
Pharma@informa.com

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: